Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...
Bio-Rad's BIO business performance has been affected by Biopharma’s softness, macroeconomic conditions in China and competitive pressure. The stock carries a Zacks Rank #4 (Sell). Since the beginning ...
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Bio-Rad Laboratories (BIO) ...
Forecasted non-GAAP operating margin excludes 103 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are ...
Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...
Have you assessed how the international operations of Bio-Rad Laboratories (BIO) performed in the quarter ended December 2025? For this maker of instruments used in biomedical research, possessing an ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for ...
Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q1 2025 CEO Norman Schwartz noted that despite macroeconomic headwinds, the company is focusing on long-term opportunities in life science ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results